Highest-materiality recent filing
Syra Health posts first profitable quarter in Q1 2026; net income $241K, EPS $0.02, revenue up 22%
Net income of $241,000 vs net loss of $(472,265) in Q1 2025; EPS $0.02 vs ($0.04).
Syra Health FY2025 net loss down 76%; Population Health revenue up 157% to $5.3M
FY2025 revenue $7.2M (-9% YoY); net loss improved 76% to ($896K) from ($3.8M).
Syra Health appoints Gregory R. Alexander as CEO effective Jan 5, 2026
New CEO Gregory R. Alexander receives $251k base salary, 30% target bonus, and 110,537 RSUs.
Syra Health Q3 revenue falls 26% to $1.7M; population health up 96%, net loss down 46%
Revenue $1.7M, down from $2.3M YoY due to federal spending cuts.
Syra Health Q2 net loss narrows 95% to $64K; gross margin surges to 38.7%
Net loss of $64K ($0.01 EPS) vs $1.4M loss ($0.21 EPS) in Q2 2024; adjusted EBITDA improved to ($54K) from ($1.4M).
Syra Health terminates CEO Deepika Vuppalanchi for cause; CFO appointed interim CEO
Board terminated CEO Deepika Vuppalanchi for cause on June 13, 2025.
Syra Health board launches national CEO search; Vuppalanchi interim
Board initiates a national search for a new CEO to succeed current CEO Dr. Deepika Vuppalanchi.
the Board of Directors of the Company appointed Priya Prasad, the Company’s CFO and COO, as interim CEO.
Max materiality 0.80 · Median 0.60 · Most common event leadership